As of early 2026, CT-388 has demonstrated some of the highest weight-loss percentages recorded in the incretin class.
: It is engineered to minimize the recruitment of -arrestin. In traditional drugs,
-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss.
As of early 2026, CT-388 has demonstrated some of the highest weight-loss percentages recorded in the incretin class.
: It is engineered to minimize the recruitment of -arrestin. In traditional drugs, ADN-388
-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss. As of early 2026, CT-388 has demonstrated some